Skip to main content
    P

    Penumbra Inc (PEN)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NYSE

    $320.63
    -0.28 (-0.09%)

    Market Cap: $12.65B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Penumbra Inc (PEN) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Penumbra (PEN) trades at 77.4x trailing earnings and 8.1x sales. Its P/E of 77.4x is below its 5-year median of 90.7x. Its forward P/E is 55.9x. The median P/E across 8 similar companies is 22.9x.

    Current Multiples

    Its forward P/E is below its trailing P/E, which implies earnings per share about 38.5% higher over the next year. Its free cash flow yield is 1.6%.

    MultipleValue
    P/E (trailing)77.4x
    Forward P/E55.9x
    Price to sales8.1x
    Price to book8.0x
    EV/EBITDA59.1x
    Price to FCF63.1x
    EV/FCF61.8x
    PEG3.6
    FCF yield1.6%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/S is 18.2% below 9.9x and its P/B is 12.1% below 9.1x.

    MultipleCurrent5-year median10-year median
    P/E77.4x90.7xN/A
    P/S8.1x8.6x9.9x
    P/B8.0x8.3x9.1x
    Medians of month-end values through Oct 2026: 54 to 60 months (5-year) and 120 months (10-year).

    Valuation History

    Over the 8 of the 10 year ends shown that have a P/E, its P/E ranged from 81.0x in 2025 to 795.5x in 2020. 2025 was the lowest of those years.

    Year endPriceP/EP/SP/B
    2025$310.9181.0x8.6x8.6x
    2024$237.4882.7x7.7x8.1x
    2023$251.54120.4x9.2x8.4x
    2022$222.46N/A10.0x8.7x
    2021$287.32410.5x14.1x11.3x
    2020$175.00795.5x11.3x10.2x
    2019$164.27169.4x10.5x12.3x
    2018$122.20239.6x9.5x10.5x
    2017$94.10174.3x9.5x8.4x
    2016$63.80N/A7.4x7.4x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About PEN

    What is PEN's forward P/E ratio?

    Penumbra has a forward P/E ratio of 55.9x.

    Is PEN stock overvalued?

    GNG's valuation label for PEN is Undervalued. Its P/E of 77.4x compares with a median of 22.9x across 8 similar companies.

    What is PEN's price to sales ratio?

    Penumbra has a price to sales ratio of 8.1x.

    What is Penumbra's average P/E ratio over 5 years?

    Penumbra's median P/E over the last 5 years is 90.7x, from 54 month-end values through Oct 2026.

    What is PEN's PEG ratio?

    Penumbra has a PEG ratio of 3.6.